Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications

Yanai, Hidekatsu; Adachi, Hisashi; Hakoshima, Mariko; Katsuyama, Hisayuki

doi:10.3390/biology12050726

Cited by 6 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report highlights a case of a 55-year-old male with T2D, demonstrating a remarkable response to imeglimin (Twymeeg) over a short period [17]. In this case, HbA1c decreased from 10.9% to 6.8% in just 3 months.…”

Section: Discussionmentioning

confidence: 65%

Improvement of HbA1c, Weight and Fatty Liver by Short Treatment of Imeglimin (Twymeeg)

Kawata,

Bando,

Kato

et al. 2024

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

The patient is a 55-year-old male with type 2 diabetes (T2D). In his 20s, 30s, and 50s, his body weight was 80 kg, 95 kg, and 90 kg, respectively. HbA1c was 10.9% in March 2023, and he was prescribed imeglimin (Twymeeg) as an oral hypoglycemic agent (OHA). HbA1c decreased to 9.3%, 7.2%, and 6.8% within just 3 months. His body weight also decreased from 86 kg to 82 kg during this period. Liver function tests showed improvement between March and May 2023, with AST decreasing from 54 to 24 U/L, ALT from 121 to 28 U/L, and GGT from 45 to 18 U/L, respectively. This suggests an improvement in fatty liver.

show abstract

Section: Discussionmentioning

confidence: 65%

Improvement of HbA1c, Weight and Fatty Liver by Short Treatment of Imeglimin (Twymeeg)

Kawata,

Bando,

Kato

et al. 2024

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

show abstract

“…Improving inflammation and stress markers may occur not only in pancreatic β-cells but also in vascular endothelium. There have been several reports about the possible effects of imeglimin on endothelial dysfunction [ 22 , 23 ]. For example, it was reported that imeglimin treatment improved endothelial function in subjects with type 2 diabetes by enhancing postprandial blood flow-mediated dilation.…”

Section: Introductionmentioning

confidence: 99%

Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ

Sanada,

Kimura,

Shimoda

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Imeglimin is a new anti-diabetic drug which promotes insulin secretion from pancreatic β-cells and reduces insulin resistance in insulin target tissues. However, there have been no reports examining the possible anti-atherosclerotic effects of imeglimin. In this study, we investigated the possible anti-atherosclerotic effects of imeglimin using atherosclerosis model ApoE KO mice treated with streptozotocin (STZ). Methods ApoE KO mice were divided into three groups: the first group was a normoglycemic group without injecting STZ (non-DM group, n = 10). In the second group, mice were injected with STZ and treated with 0.5% carboxymethyl cellulose (CMC) (control group, n = 12). In the third group, mice were injected with STZ and treated with imeglimin (200 mg/kg, twice daily oral gavage, n = 12). We observed the mice in the three groups from 10 to 18 weeks of age. Plaque formation in aortic arch and expression levels of various vascular factors in abdominal aorta were evaluated for each group. Results Imeglimin showed favorable effects on the development of plaque formation in the aortic arch in STZ-induced hyperglycemic ApoE KO mice which was independent of glycemic and lipid control. Migration and proliferation of vascular smooth muscle cells and infiltration of macrophage were observed in atherosclerotic lesions in STZ-induced hyperglycemic ApoE KO mice, however, which were markedly reduced by imeglimin treatment. In addition, imeglimin reduced oxidative stress, inflammation and inflammasome in hyperglycemic ApoE KO mice. Expression levels of macrophage makers were also significantly reduced by imeglimin treatment. Conclusions Imeglimin exerts favorable effects on the development of plaque formation and progression of atherosclerosis.

show abstract

“…Imeglimin Hydrochloride (also called Imeglimin) a recently approved oral anti-diabetic drug is a first of the class of tetrahydratriazone drug called "glimins" [9]. Chemically Imeglimin Hydrochloride is-(R)-6-imino-N,N,4-trimethyl-1,4,5,6-tetrahydro-1,3,5-triazin-2-amine hydrochloride.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of Stability Indicating Rp-Uhplc Method for the Estimation of Imeglimin Hydrochloride Used for the Treatment of Metabolic Disorder Diabetes Mellitus

JAIN,

SONI,

SHARMA

2023

Int J App Pharm

View full text Add to dashboard Cite

Objective: The present work was aimed to develop and validate a novel, simple, rapid, consistent, and sensitive stability indicating reverse phase ultra-high-performance liquid chromatographic (RP-UHPLC) method for the determination of oral anti-diabetic drug Imeglimin Hydrochloride in bulk and pharmaceuticals dosage form as per the technical recommendations of International Council for Harmonization guidelines for human use pharmaceutical (ICH-Q2(R1)). Methods: A novel simple, selective, stable and sensitive stability indicating method which used isocratic RP-UHPLC methodology for the quantitative measurement of Imeglimin Hydrochloride was developed. The chromatographic separation of Imeglimin Hydrochloride was achieved on RP-UHPLC equipped with Hypersil gold ODS endcapped column of dimensions (150x4.6 mm, 3micron) using isocratic elution with a mobile phase consisting of water: acetonitrile in a ratio of (15:85% v/v) at a flow rate of 1 ml/min with an injection volume of 20 µl. All measurements are done on 240 nm using eight channels Dionex Ultimate 3000 PDA detector equipped with chromeleon data acquisition system for data integration. Validation of the proposed method was carried out according to the (ICH-Q2 (R1)) guidelines. Results: The retention time of the Imeglimin Hydrochloride was found to be 3.831 with excellent absorbance sensitivity at 240 nm wavelength. The linear regression equation was found to be y = 3199x+1605.5 with a correlation coefficient (R2)>0.999 which shows excellent linear correlation. Specificity, linearity, precision, accuracy robustness, LOD and LOQ were determined for method validation and results were found to be well within recommended limits as per ICH guidelines. Conclusion: The proposed stability indicating reverse phase ultra-high-performance liquid chromatographic (RP-UHPLC) method was found to be fast, affordable, robust, precise and specific for estimation of Imeglimin Hydrochloride in pharmaceutical dosage form.

show abstract

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications

Cited by 6 publications

References 78 publications

Improvement of HbA1c, Weight and Fatty Liver by Short Treatment of Imeglimin (Twymeeg)

Improvement of HbA1c, Weight and Fatty Liver by Short Treatment of Imeglimin (Twymeeg)

Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ

Development and Validation of Stability Indicating Rp-Uhplc Method for the Estimation of Imeglimin Hydrochloride Used for the Treatment of Metabolic Disorder Diabetes Mellitus

Contact Info

Product

Resources

About